Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Lowers PT on Abbott Laboratories

Related ABT
Top 4 NYSE Stocks In The Medical Appliances & Equipment Industry With The Highest Revenue
5 Companies That Have Moved Overseas For Lower Taxes
Buyback Mania Inflates 2Q Earnings Growth (Fox Business)

In a report published Wednesday, Jefferies & Company reiterated its Buy rating on Abbott Laboratories (NYSE: ABT), but lowered its price target from $87.00 to $39.00.

Jefferies & Company noted, “We see Pharmaceuticals as remaining attractive in 2013, but unlikely to return the same level of relative performance as in 2012. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche, Pfizer and Bristol-Myers remain high conviction Buy ratings. We continue to point to Eli Lilly and GlaxoSmithKline as our least preferred names.”

Abbott Laboratories closed on Tuesday at $33.36.

Latest Ratings for ABT

DateFirmActionFromTo
Jul 2014BarclaysMaintainsEqual-weight
Jul 2014Raymond JamesMaintainsOutperform
Jul 2014JefferiesMaintainsBuy

View More Analyst Ratings for ABT
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (ABT)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters